Cited 6 time in
Identification of 4 '-O-beta-D-glucosyl-5-O-methylvisamminol as a novel epigenetic suppressor of histone H3 phosphorylation at Ser10 and its interaction with 14-3-3 epsilon
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kang, Jong-Su | - |
| dc.contributor.author | Chin, Young-Won | - |
| dc.contributor.author | Lee, Kyeong | - |
| dc.contributor.author | Kim, Young-Woo | - |
| dc.contributor.author | Choi, Bu Young | - |
| dc.contributor.author | Keum, Young-Sam | - |
| dc.date.accessioned | 2024-08-08T01:31:16Z | - |
| dc.date.available | 2024-08-08T01:31:16Z | - |
| dc.date.issued | 2014-10-01 | - |
| dc.identifier.issn | 0960-894X | - |
| dc.identifier.issn | 1464-3405 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/15263 | - |
| dc.description.abstract | Natural compounds are regarded as a rich source for potential anti-inflammatory and anti-carcinogenic agents. Increasing evidence indicates that histone phosphorylation at Ser10 is a marker for cell cycle progression during the mitosis and the induction of immediate pro-inflammatory genes during the interphase. In the present study, we have screened our in-house natural compounds to find out new chemical inhibitor(s) of histone H3 phosphorylation at Ser10. As a result, we observed that alpha-amyrin, oleanolic acid, marliolide, and 4'-O-beta-D-glucosyl-5-O-methylvisamminol decreased the levels of histone H3 phosphorylation at Ser10 and c-Jun. In particular, we observed that 4'-O-beta-D-glucosyl-5-O-methylvisamminol suppressed the direct interaction of histone H3 with 14-3-3 epsilon, inhibited the aurora B kinase activity and delayed the mitotic cell cycle progression. We reports 4'-0-beta-D-glucosyl-5-O-methylvisamminol as the first epigenetic natural chemical inhibitor that can abrogates the mitotic cell cycle progression and immediate pro-inflammatory gene expressions via suppression of histone H3 phosphorylation at Ser10 and its interaction with 14-3-3 epsilon. (C) 2014 Elsevier Ltd. All rights reserved. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
| dc.title | Identification of 4 '-O-beta-D-glucosyl-5-O-methylvisamminol as a novel epigenetic suppressor of histone H3 phosphorylation at Ser10 and its interaction with 14-3-3 epsilon | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.bmcl.2014.07.005 | - |
| dc.identifier.scopusid | 2-s2.0-84907204524 | - |
| dc.identifier.wosid | 000342574600028 | - |
| dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.24, no.19, pp 4763 - 4767 | - |
| dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
| dc.citation.volume | 24 | - |
| dc.citation.number | 19 | - |
| dc.citation.startPage | 4763 | - |
| dc.citation.endPage | 4767 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
| dc.subject.keywordPlus | 14-3-3 PROTEINS | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordAuthor | 4 '-O-beta-D-Glucosyl-5-O-methylvisamminol | - |
| dc.subject.keywordAuthor | Histone phosphorylation | - |
| dc.subject.keywordAuthor | 14-3-3 epsilon | - |
| dc.subject.keywordAuthor | Aurora B kinase | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
